{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:44:59Z","timestamp":1776681899426,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T00:00:00Z","timestamp":1362182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00393-012-1063-z","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T03:21:11Z","timestamp":1362108071000},"page":"339-346","source":"Crossref","is-referenced-by-count":5,"title":["Biologikaregister JuMBO","Biologics register JuMBO"],"prefix":"10.1007","volume":"72","author":[{"given":"K.","family":"Minden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Niewerth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,2]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis JR et al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:1263\u20131271","journal-title":"Arthritis Rheum"},{"key":"1063_CR2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","volume":"62","author":"Diak","year":"2010","unstructured":"Diak P, Siegel J, La Grenade L et al (2010) Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis Rheum 62:2517\u20132524","journal-title":"Arthritis Rheum"},{"key":"1063_CR3","first-page":"386","volume":"30","author":"Flat\u00f8","year":"2003","unstructured":"Flat\u00f8 B, Lien G, Smerdel A et al (2003) Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 30:386\u2013393","journal-title":"J Rheumatol"},{"key":"1063_CR4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.10863","volume":"48","author":"Foster","year":"2003","unstructured":"Foster HE, Marshall N, Myers A et al (2003) Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 48:767\u2013775","journal-title":"Arthritis Rheum"},{"key":"1063_CR5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145","journal-title":"Arthritis Rheum"},{"key":"1063_CR6","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"Giannini","year":"2009","unstructured":"Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794\u20132804","journal-title":"Arthritis Rheum"},{"key":"1063_CR7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638\u20131644","journal-title":"Ann Rheum Dis"},{"key":"1063_CR8","doi-asserted-by":"crossref","unstructured":"Horneff G, Foeldvari I, Minden K et al (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 50:230\u2013236","DOI":"10.1093\/rheumatology\/keq361"},{"key":"1063_CR9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763\u2013769","journal-title":"N Engl J Med"},{"key":"1063_CR10","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496\u20131504","journal-title":"Arthritis Rheum"},{"key":"1063_CR11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810\u2013820","journal-title":"N Engl J Med"},{"key":"1063_CR12","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/art.10444","volume":"46","author":"Minden","year":"2002","unstructured":"Minden K, Niewerth M, Listing J et al (2002) Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:2392\u20132401","journal-title":"Arthritis Rheum"},{"key":"1063_CR13","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","volume":"Res","author":"Nordstrom","year":"2012","unstructured":"Nordstrom BL, Mines D, Gu Y et al (2012) Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken) 64:1357\u20131364","journal-title":"Arthritis Care"},{"key":"1063_CR14","first-page":"1989","volume":"29","author":"Oen","year":"2002","unstructured":"Oen K, Malleson PN, Cabral DA et al (2002) Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 29:1989\u20131999","journal-title":"J Rheumatol"},{"key":"1063_CR15","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","volume":"306","author":"Otten","year":"2011","unstructured":"Otten MH, Prince FHM, Armbrust W et al (2011) Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306:2340\u20132347","journal-title":"JAMA"},{"key":"1063_CR16","doi-asserted-by":"crossref","unstructured":"Packham JC, Hall MA (2002) Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 41:1428\u20131435","DOI":"10.1093\/rheumatology\/41.12.1428"},{"key":"1063_CR17","first-page":"390","volume":"31","author":"Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"1063_CR18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","volume":"68","author":"Prince","year":"2009","unstructured":"Prince FHM, Twilt M, ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68:635\u2013641","journal-title":"Ann Rheum Dis"},{"key":"1063_CR19","unstructured":"Robert-Koch-Institute (1998) Public use file. National Health Survey"},{"key":"1063_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383\u2013391","journal-title":"Lancet"},{"key":"1063_CR21","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","volume":"62","author":"Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792\u20131802","journal-title":"Arthritis Rheum"},{"key":"1063_CR22","doi-asserted-by":"crossref","unstructured":"Sevcic K, Orban I, Brodszky V et al (2011) Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology (Oxford) 50:1337\u20131340","DOI":"10.1093\/rheumatology\/ker103"},{"key":"1063_CR23","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","volume":"62","author":"Simard","year":"2010","unstructured":"Simard JF, Neovius M, Hagelberg S, Askling J (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62:3776\u20133782","journal-title":"Arthritis Rheum"},{"key":"1063_CR24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3899\/jrheum.100809","volume":"38","author":"Dijken","year":"2011","unstructured":"Dijken TD van, Vastert SJ, Gerloni VM et al (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38:1441\u20131446","journal-title":"J Rheumatol"},{"key":"1063_CR25","first-page":"2290","volume":"31","author":"Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31:2290\u20132294","journal-title":"J Rheumatol"},{"key":"1063_CR26","unstructured":"Ware J, Snow K, Kosinski M (1997) SF-36 health survey. Manual and interpretation guide. The National Health Institute, New England Medical Center, Boston"},{"key":"1063_CR27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00393-006-0033-8","volume":"65","author":"Zink","year":"2006","unstructured":"Zink A, Listing J, Strangfeld A et al (2006) Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT. Z Rheumatol 65:441\u2013446","journal-title":"Z Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-1063-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-012-1063-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-1063-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:12Z","timestamp":1559061372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-012-1063-z"}},"subtitle":["Langzeitsicherheit von Biologikatherapie bei juveniler idiopathischer Arthritis","Long-term safety of biologic therapy of juvenile idiopathic arthritis"],"short-title":[],"issued":{"date-parts":[[2013,3,2]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s00393-012-1063-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,2]]}}}